NASDAQ:INSM 13 August 2025

CoreWeave edges higher before Nasdaq-100 debut, week looks ahead to debt moves

CoreWeave shares ended the week up during the abbreviated U.S. trading week, as investors adjusted portfolios ahead of the AI cloud company joining the Nasdaq-100 at Monday’s open. The move can trigger buying from index-tracking funds.

20 June 2026

Nasdaq·NASDAQ:AXLA·NASDAQ:CHTR·NASDAQ:CTSH·NASDAQ:INSM·NASDAQ:META·NASDAQ:RKLB·NASDAQ:TER·NASDAQ:VRSK·NASDAQ:ZS·Stock Market

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia Corp shares slid about 8% in afternoon trade on Friday, giving back earlier gains and underperforming the broader biotech group. The stock was down $2.79 at $31.70, after trading between $30.76 and $34.97. Volume topped 1.88 million shares.

2 January 2026

NASDAQ:INSM·NASDAQ:LQDA·NASDAQ:UTHR·Stock Market

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed Incorporated ended Monday’s session slightly higher and then traded in a tight range after the closing bell, as investors weighed two forces that have been shaping the stock into year-end: Nasdaq-100 inclusion and the market’s continuing digestion of last week’s brensocatib CRSsNP trial miss. StockAnalysis+2Mondo Visione+2

23 December 2025

Nasdaq-100·NASDAQ:INSM·Stock Market

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed Incorporated is ending 2025 with two headlines pulling the stock in opposite directions: fresh visibility from joining the Nasdaq‑100 Index and fresh volatility after a clinical disappointment for a key expansion effort.

22 December 2025

NASDAQ:INSM·Stock Market

Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Insmed Incorporated heads into the Monday, Dec. 22, 2025 session with two powerful—almost opposing—forces in play: a fresh clinical disappointment that jolted sentiment last week, and a major index catalyst that can drive mechanical buying at the open.

22 December 2025

NASDAQ:INSM·Stock Market

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Insmed Incorporated is heading into a pivotal trading week with two narratives pulling on sentiment at the same time:

21 December 2025

Nasdaq-100·NASDAQ:INSM

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

December 20, 2025 — Insmed Incorporated is ending the week in “re-pricing mode” after a mid-stage clinical setback jolted investor expectations, sparked sharp volatility, and triggered a round of analyst price-target revisions. By Friday’s close, Insmed shares finished at $174.84, up about 5% on the day—recovering some ground after Thursday’s steep drop.

20 December 2025

Financial Forecasts·NASDAQ:INSM·Stock Market

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed Incorporated closed out a turbulent week with a sharp rebound on Friday, Dec. 19, 2025, and the move largely held after the bell—a sign that investors may be trying to stabilize expectations after the company’s latest clinical update whipsawed the stock earlier in the week.

20 December 2025

NASDAQ:INSM·Stock Market

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

December 19, 2025 — Insmed Incorporated is back in focus today after a sharp, news-driven selloff on Thursday and a noticeable bounce on Friday. As of 15:46 UTC on Dec. 19, INSM shares were trading around $174.90, up roughly $8.35 versus the prior close, with the day’s range spanning about $166.01 to $174.90.

19 December 2025

NASDAQ:INSM·Stock Market

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously added a new Phase 2–ready antibody to its pipeline. SEC+1

18 December 2025

Biotechnology·Earnings Reports·NASDAQ:INSM·Stock Market

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Sources: Official press releases, government health agency updates, and reputable media coverage were used in this report. All source links are provided inline above for reference.

14 August 2025

NASDAQ:BHVN·NASDAQ:INSM·NYSE:NVS·Stock Market

Tech World Rocked by 8 Non‑AI Surprises This Week

August 13–14, 2025 – It’s not all about AI – the past two days delivered a whirlwind of tech news across industries, from surprise gadget revivals and space milestones to major moves in finance, health, and cybersecurity. Here’s a roundup of the biggest developments shaking up the tech world:

14 August 2025

Innovation·NASDAQ:AAPL·NASDAQ:AMD·NASDAQ:AMZN·NASDAQ:INSM·NASDAQ:META·NASDAQ:NVDA·NASDAQ:SMCI·NASDAQ:TSLA·NYSE:DELL·Technology·Trends

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthroughs in Biotech & Pharma Big Deals and Industry Moves Regulatory & Health Policy Updates Public Health Developments Noteworthy Medical Research Healthcare Technology Advancements

13 August 2025

NASDAQ:INSM·NYSE:BHVN·NYSE:NVS·Pharmaceutical News

NASDAQ:INSM 13 August 2025 - 20 June 2026